Business Description
BioXcel Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US09075P2048
Total Employee Number:
29Description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.12 | |||||
Equity-to-Asset | -4.01 | |||||
Debt-to-Equity | -0.91 | |||||
Debt-to-EBITDA | -1.96 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -46.95 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -37.2 | |||||
3-Year EBITDA Growth Rate | 63.7 | |||||
3-Year EPS without NRI Growth Rate | 60.8 | |||||
3-Year FCF Growth Rate | 60.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 55.97 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 536.88 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 10.72 | |||||
9-Day RSI | 18.38 | |||||
14-Day RSI | 24.23 | |||||
3-1 Month Momentum % | -36.46 | |||||
6-1 Month Momentum % | -51.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.21 | |||||
Quick Ratio | 0.21 | |||||
Cash Ratio | 0.09 | |||||
Days Inventory | 560.09 | |||||
Days Sales Outstanding | 67.39 | |||||
Days Payable | 17347.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -133.3 | |||||
Shareholder Yield % | -984.77 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 53.1 | |||||
Operating Margin % | -6028.57 | |||||
Net Margin % | -9549.87 | |||||
EBITDA Margin % | -7198.25 | |||||
FCF Margin % | -6841.69 | |||||
OCF Margin % | -6841.69 | |||||
ROA % | -198.69 | |||||
ROIC % | -105.87 | |||||
3-Year ROIIC % | 433.15 | |||||
ROC (Joel Greenblatt) % | -19405.21 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.5 | |||||
EV-to-EBIT | -1.81 | |||||
EV-to-EBITDA | -1.82 | |||||
EV-to-Forward-EBITDA | -2.69 | |||||
EV-to-Revenue | 131.12 | |||||
EV-to-Forward-Revenue | 71.79 | |||||
EV-to-FCF | -1.91 | |||||
Price-to-GF-Value | 0.4 | |||||
Earnings Yield (Greenblatt) % | -55.25 | |||||
FCF Yield % | -896.2 |
BioXcel Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioXcel Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-11 09:00 | In 103 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 73 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 0.76 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.02 (+0.00%) | ||
| Annual report for 2025 | 2026-03-27 | 1.25 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 1.25 (+0.00%) | ||
| General meeting for 2025 | 2025-12-12 09:00 | -- | ||
| Third quarter earnings results for 2025 | 2025-11-12 | -- | ||
| Bioxcel Therapeutics SERENITY At-Home Pivotal Phase 3 Safety Trial Results | 2025-09-10 14:00 | -- | ||
| H.C. Wainwright 27(th) Annual Global Investment Conference | 2025-09-08 16:30 | -- |
Show
Entries
Press Release
Articles on BioXcel Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers